Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
Feb 20 (Reuters) - Guerbet SA GRBT.PA: NEW INDICATION IN PEDIATRIC PATIENTS, INCLUDING TERM NEONATES FOR GUERBET'S HALF-DOSE GBCA, ELUCIREM™ (GADOPICLENOL) INJECTION GUERBET SA - FDA APPROVES LABELING UPDATE FOR GUERBET'S ELUCIREM INJECTION GUERBET SA - NEW INDICATION INCLUDES APPROVAL FOR PEDIATRIC PATIENTS AGED 0-2 YEARS FOR ELUCIREM Source text: ID:nPn7Chz2va Further company coverage: GRBT.PA ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on Guerbet SA
See all newsBrief: Guerbet Q1 Revenue At EUR 177.4 Mln
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates